KRAS and neoplasm: This is exemplified in the work undertaken by Trang et al. where they found that the systemic delivery of miRNA let-7 or miR-34 using neutral LNPs led to a significant reduction in tumour size in a mouse model of NSCLC with KRAS G12D mutation [105].